Hepatitis C virus core protein-induced miR-93-5p up-regulation inhibits interferon signaling pathway by targeting IFNAR1

Table 1 Characteristics of patients with hepatitis C virus-1b infection

Variable	High expression of miR-93-5p	Low expression of miR-93-5p	P value
Gender			0.382
Male	25	20
Female	17	22
Age			0.189
Median
>44	19	26
≤44	23	16
HCV-1b treatment			0.001
Resistance	25	9
Sensitivity	17	33

Differences between variables were analyzed by the χ² test. HCV: Hepatitis C virus.

Table 2 Primers sequences

mRNA	Sequence
β-actin forward	5’-TGTCCACCTTCCAGCAGATGT-3’
β-actin reverse	5’-TGTCACCTTCACCGTTCCAGTT-3’
IFNAR1 forward	5’-TGGTGACAGCGTGAGACTCTT-3’
IFNAR1 reverse	5’-GCAGTAGCCAGCAGCATCAG-3’
MiR-93-5p forward	5′- GCCGCCAAAGTGCTGTTC-3′
MiR-93-5p reverse	5′-CAGAGCAGGGTCCGAGGTA-3′
U6 forward	5′-CAGCACATATACTAAAATTGGAACG-3′
U6 reverse	5′-ACGAATTTGCGTGTCATCC-3′

IFNAR1: Interferon receptor 1.

Table 3 Receiver operating characteristics curve analysis of serum miR-93-5p concentration

AUC	Sensitivity	Specificity	Cut-off value (amol/μL)
0.8846 (Infection vs Healthy)	0.7619	1	0.009774
0.8562 (Sensitivity vs Healthy)	0.7000	1	0.009774
0.9265 (Infection vs Resistance)	0.8529	1	0.010870
0.8359 (Resistance vs Sensitivity)	0.7647	1	0.030300

Infection: HCV-1b-infected patients; Healthy: Healthy subjects; Sensitivity: Patients with pegylated IFNα sensitivity; Resistance: Patients with pegylated IFNα resistance.